|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||108.07 - 110.25|
|52-week range||85.05 - 126.70|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||36.51|
|Forward dividend & yield||2.79 (2.60%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||N/A|
Detailed results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab, a potential first-in-class treatment, demonstrated superiority across every primary and key secondary endpoint in a broad population of severe asthma patients, compared to placebo when added to standard of care (SoC).
POSEIDON was a Phase III trial of AstraZeneca’s IMFINZI® (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
AstraZeneca’s FARXIGA® (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.